Related Experiment Video
Updated: Mar 26, 2026
06:35
An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
Published on: February 8, 2019
7.9K
Dabigatran Associated Leukocytoclastic Vasculitis.
Evangelos Potolidis1, Charalampos Mandros1, Kalliopi Kotsa2
1Department of Internal Medicine B, General Hospital of Volos, 38221 Volos, Greece.
Case Reports in Medicine
|February 5, 2016
Summary
Dabigatran, a common anticoagulant, can cause rare skin reactions like leukocytoclastic vasculitis. This case highlights a resistant reaction in a 70-year-old male, emphasizing the need for awareness.
Area of Science:
- Pharmacology
- Dermatology
- Internal Medicine
Background:
- Dabigatran is a direct thrombin inhibitor used for anticoagulation.
- While generally safe, dabigatran can cause various side effects, with skin reactions being uncommon (<0.1%).
- Leukocytoclastic vasculitis is an inflammation of small blood vessels.
Purpose of the Study:
- To report a rare case of dabigatran-induced skin reaction.
- To describe a specific type of skin reaction: leukocytoclastic vasculitis.
- To highlight a case resistant to standard treatments.
Main Methods:
- A 70-year-old male patient developed a skin reaction after starting dabigatran.
- The reaction was resistant to conventional therapies.
- A skin biopsy was performed for diagnosis.
Main Results:
- The patient experienced a skin reaction attributed to dabigatran.
- Skin biopsy results confirmed leukocytoclastic vasculitis.
- The reaction did not respond to standard treatment protocols.
Conclusions:
- Dabigatran can rarely cause severe skin reactions, including leukocytoclastic vasculitis.
- Such reactions may be refractory to common therapeutic approaches.
- This case underscores the importance of considering drug-induced vasculitis in patients on dabigatran presenting with resistant skin manifestations.
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
460
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
460
01:30Venous Thrombosis I: Introduction
668
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
668
01:20Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
433
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
433
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.7K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.7K
01:25Endocarditis II: Clinical Features of Infective Endocarditis
748
Endocarditis can present various clinical features depending on the causative organism and the patient's underlying health conditions. Initially, the clinical features of infective endocarditis develop gradually, presenting with nonspecific symptoms that can be easily mistaken for other illnesses.General SymptomsEarly symptoms of infective endocarditis are fever, chills, weakness, malaise, fatigue, and weight loss. These symptoms reflect the systemic nature of the infection and the body's...
748
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.3K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.3K